Newer oral anticoagulants offer predictable pharmacokinetics and do not require routine monitoring, overcoming the limitations of traditional vitamin K antagonists for stroke prevention in atrial fibrillation.
May ease AF anticoagulation management; leaves open need for updated comparative trials versus VKAs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: